Profound Medical Corp. (T:PRN)
Business Focus: Advanced Medical Equipment & Technology (NEC)
Apr 09, 2024 07:45 am ET
Profound Medical to Participate in the 2024 Bloom Burton & Co. Healthcare Investor Conference
Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today announced that...
Mar 07, 2024 04:05 pm ET
Profound Medical Announces Fourth Quarter and Full Year 2023 Financial Results
Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today reported financial...
Mar 04, 2024 04:30 pm ET
Profound Medical to Participate in Barclays 26th Annual Global Healthcare Conference
Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today announced that...
Feb 27, 2024 07:45 am ET
Profound Medical in Collaboration with Siemens Healthineers to Further Expand Physician and Patient Access to the TULSA Procedure
Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today announced that it has...
Feb 15, 2024 04:30 pm ET
Profound Medical to Release Fourth Quarter and Full Year 2023 Financial Results on March 7 – Conference Call to Follow
Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, will announce its fourth...
Jan 16, 2024 04:30 pm ET
Profound Medical Announces Non-Brokered Private Placement
Profound Medical Corp. (TSX:PRN; NASDAQ:PROF) ("Profound" or the "Company") is pleased to announce that the Company has entered into subscription agreements, dated as of January 16, 2024, with certain existing Canadian institutional investors, in...
Jan 03, 2024 04:15 pm ET
Profound Medical Announces Preliminary Unaudited Fourth Quarter and Full Year 2023 Revenues
Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today announced preliminary...
Dec 27, 2023 10:40 pm ET
Profound Medical Announces Pricing of US$20 Million Public Offering of Common Shares
Profound Medical Corp. (TSX:PRN; NASDAQ:PROF) (“Profound” or the “Company”) today announced the pricing of its previously announced underwritten public offering (the “Offering”) of 2,666,667 common shares (the “Common Shares”) at a price to the...
Dec 27, 2023 04:15 pm ET
Profound Medical Announces Proposed Public Offering of Common Shares
Profound Medical Corp. (TSX:PRN; NASDAQ:PROF) (“Profound” or the “Company”) is pleased to announce the commencement of an underwritten public offering in the United States of common shares (the “Common Shares”) in the capital of the Company (the...
Nov 08, 2023 07:45 am ET
Profound Medical to Participate in the Stifel 2023 Healthcare Conference
Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today announced that...
Nov 03, 2023 08:00 am ET
Profound Medical Announces CMS Extension of Temporary ‘Code’ for TULSA to ASC Setting
Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, announced today that,...
Nov 02, 2023 04:05 pm ET
Profound Medical Announces Third Quarter 2023 Financial Results
Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today reported financial...
Oct 19, 2023 04:30 pm ET
Profound Medical to Release Third Quarter 2023 Financial Results on November 2 – Conference Call to Follow
Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, will announce its third...
Oct 10, 2023 04:30 pm ET
Profound Medical 2023 Virtual Analyst & Investor Day Agenda
Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, announced today additional...
Sep 25, 2023 04:05 pm ET
Profound Medical Receives U.S. FDA 510(k) Clearance for TULSA-PRO® Thermal Boost
Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today announced that it has...
Sep 21, 2023 08:00 am ET
Save the Date: Profound Medical to Host Virtual Analyst & Investor Day on October 13
Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, will host an Analyst &...
Sep 19, 2023 04:45 pm ET
Profound Medical to Participate in the 2023 Cantor Global Healthcare Conference
Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today announced that...
Sep 06, 2023 07:23 pm ET
Profound Medical Announces At-the-Market Offering of up to US$30,000,000
Profound Medical Corp. (TSX: PRN; NASDAQ: PROF) (“Profound” or the “Company”) announces that it has established an at-the-market equity program (the “ATM Program”) that allows the Company, through certain securities dealers acting as agents...
Aug 09, 2023 04:05 pm ET
Profound Medical Announces Second Quarter 2023 Financial Results
Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today reported financial...
Aug 02, 2023 04:30 pm ET
Profound Medical to Release Second Quarter 2023 Financial Results on August 9 – Conference Call to Follow
Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, will announce its second...
Jun 02, 2023 01:40 pm ET
Profound Medical Announces New CPT® Category 1 Codes from the AMA for TULSA to Treat Prostate Diseases
Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, announced today that, with...
May 30, 2023 08:00 am ET
Profound Medical Announces Upcoming Investor Events
Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, announces the following...
May 18, 2023 08:00 am ET
Profound Medical to Participate in A.G.P.’s Virtual Healthcare Conference
Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, announced that management...
May 17, 2023 04:15 pm ET
Profound Medical Annual and Special Meeting of Shareholders Voting Results
Profound Medical Corp. (TSX: PRN; NASDAQ: PROF) (“Profound” or the “Company”) is pleased to announce the voting results from its Annual and Special Meeting of Shareholders that was held today (the “Meeting”). A total of 13,437,920 common shares,...
May 10, 2023 04:05 pm ET
Profound Medical Announces First Quarter 2023 Financial Results
Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today reported financial...
May 01, 2023 04:30 pm ET
TULSA Procedure Featured in the Scientific Program at the American Urological Association 2023 Annual Meeting
Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today announced the...
Apr 19, 2023 04:30 pm ET
Profound Medical to Release First Quarter 2023 Financial Results on May 10 – Conference Call to Follow
Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, will announce its first...
Apr 19, 2023 04:15 pm ET
Profound Medical to to Participate in the 2023 Bloom Burton & Co. Healthcare Investor Conference
Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today announced that...
Mar 07, 2023 04:05 pm ET
Profound Medical Announces Fourth Quarter and Full Year 2022 Financial Results
Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today reported financial...
Mar 01, 2023 04:30 pm ET
Profound Medical to Present at the 43rd Annual Cowen Health Care Conference
Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today announced that its CEO...
Feb 14, 2023 04:30 pm ET
Profound Medical to Release Fourth Quarter and Full Year 2022 Financial Results on March 7 – Conference Call to Follow
Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, will announce its fourth...
Nov 08, 2022 04:30 pm ET
Profound Medical to Present at the 2022 Jefferies London Healthcare Conference
Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today announced that its CEO...
Nov 03, 2022 04:05 pm ET
Profound Medical Announces Third Quarter 2022 Financial Results
Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today reported financial...
Oct 13, 2022 04:30 pm ET
Profound Medical to Release Third Quarter 2022 Financial Results on November 3 – Conference Call to Follow
Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, will announce its third...
Sep 26, 2022 08:00 am ET
Four Year Follow-Up Data from Profound Medical’s TACT Pivotal Clinical Trial Confirm Durable and Stable Positive Trends Following Treatment with TULSA-PRO® of Men with Localized Prostate Cancer
Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, announced that updated...
Sep 15, 2022 08:00 am ET
Profound Medical Announces Changes to its Commercial Organization to Support Continued Growth
Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today announced changes to...
Sep 06, 2022 04:30 pm ET
Profound Medical to Participate in September Investor Conferences
Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today announced that...
Sep 02, 2022 12:05 pm ET
Profound Medical Provides TULSA-PRO® Reimbursement Update
Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today provided a U.S....
Aug 04, 2022 04:05 pm ET
Profound Medical Announces Second Quarter 2022 Financial Results
Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today reported financial...
Jul 14, 2022 04:30 pm ET
Profound Medical to Release Second Quarter 2022 Financial Results on August 4 – Conference Call to Follow
Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, will announce its second...
Jun 16, 2022 04:30 pm ET
Profound Medical to Participate in the Cowen 7th Annual FutureHealth Conference
Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today announced that its CEO...
Jun 02, 2022 04:30 pm ET
Profound Medical to Participate in the 2022 Jefferies Global Healthcare Conference
Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today announced that...
May 18, 2022 05:43 pm ET
Profound Medical Annual and Special Meeting of Shareholders Voting Results
Profound Medical Corp. (TSX: PRN; NASDAQ: PROF) (“Profound” or the “Company”) is pleased to announce the voting results from its Annual and Special Meeting of Shareholders that was held today (the “Meeting”). A total of 12,858,319 common shares,...
May 18, 2022 04:30 pm ET
Profound Medical Clarifies Recent Insider Buying
In response to investor inquiries regarding insider trading activity, particularly with respect to recent open market stock purchases made by certain of its insiders, Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”) today...
May 17, 2022 05:25 pm ET
TULSA-PRO® Was Front and Center at AUA2022
Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today announced that...
May 09, 2022 04:05 pm ET
Profound Medical Announces First Quarter 2022 Financial Results
Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today reported financial...
Apr 25, 2022 04:30 pm ET
Profound Medical to Participate in the 2022 Bloom Burton & Co. Healthcare Investor Conference
Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today announced that...
Apr 18, 2022 04:30 pm ET
Profound Medical to Release First Quarter 2022 Financial Results on May 9 – Conference Call to Follow
Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, will announce its first...
Mar 03, 2022 04:03 pm ET
Profound Medical Announces Fourth Quarter and Full Year 2021 Financial Results
Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today reported financial...
Mar 02, 2022 08:00 am ET
Profound Medical to Participate in March Investor Conferences
Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today announced that...
Mar 01, 2022 07:00 am ET
Profound Medical’s TULSA-PRO® Now Compatible with GE Healthcare’s 3T MRI Scanners
Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today confirmed the...
Feb 10, 2022 04:30 pm ET
Profound Medical to Release Fourth Quarter and Full Year 2021 Financial Results on March 3 – Conference Call to Follow
Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, will announce its fourth...
Feb 08, 2022 04:30 pm ET
Profound Medical to Participate in the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Virtual Conference
Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today announced that...
Jan 18, 2022 07:33 am ET
Profound Medical Announces First Patients Treated in Prospective, Randomized Clinical Trial Comparing the TULSA Procedure to Radical Prostatectomy
Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today announced that the...
Jan 05, 2022 08:00 am ET
Kenneth Knudson Joins Profound Medical as Chief Commercial Officer
Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today announced the...
Nov 04, 2021 04:03 pm ET
Profound Medical Announces Third Quarter 2021 Financial Results
Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today reported financial...
Nov 01, 2021 04:30 pm ET
Profound Medical to Participate in November Virtual Investor Conferences
Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, announced today that...
Oct 18, 2021 04:45 pm ET
Profound Medical to Release Third Quarter 2021 Financial Results on November 4 – Conference Call to Follow
Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, will announce its third...
Sep 08, 2021 04:30 pm ET
Profound Medical to Participate in September Virtual Investor Conferences
Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, announce today that...
Aug 04, 2021 04:05 pm ET
Profound Medical Announces Second Quarter 2021 Financial Results
Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today reported financial...
Jul 22, 2021 04:30 pm ET
Profound Medical to Participate in A.G.P.’s Virtual MedTech Summer Conference
Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, announced today that...
Jul 15, 2021 04:30 pm ET
Profound Medical to Release Second Quarter 2021 Financial Results on August 4 – Conference Call to Follow
Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, will announce its second...
May 25, 2021 04:30 pm ET
Profound Medical to Participate in June Investor Conferences
Profound Medical Corp. (TSX: PRN; NASDAQ: PROF) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, announced today that...
May 19, 2021 04:30 pm ET
Profound Medical Announces Voting Results from the 2021 Annual Meeting of Shareholders and Management Changes
Profound Medical Corp. (TSX: PRN; NASDAQ: PROF) (“Profound” or the “Company”) is pleased to announce the voting results from its Annual Meeting of Shareholders that was held today (the “Meeting”). A total of 11,810,287 common shares, representing...
May 12, 2021 04:13 pm ET
Profound Medical Announces First Quarter 2021 Financial Results
Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today reported financial...
May 06, 2021 07:00 am ET
Akumin and Profound Medical Enter into U.S. Multi-Center Commercial Agreement for TULSA-PRO®
PLANTATION, Fla., May 6, 2021 /CNW/ - Akumin Inc. (NASDAQ: AKU) (TSX: AKU) ("Akumin"), a leading provider of freestanding, fixed-site outpatient diagnostic imaging services in the United States, today announced the signing of a multi-site imaging center agreement for TULSA-PRO® with Profound Medical Corp. (NASDAQ: PROF) (TSX: PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue.
May 06, 2021 07:00 am ET
Profound Medical and Akumin Enter into U.S. Multi-Center Commercial Agreement for TULSA-PRO®
Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today announced the signing...
Apr 21, 2021 04:30 pm ET
Profound Medical to Release First Quarter 2021 Financial Results on May 12 – Conference Call to Follow
Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, will announce its first...
Apr 14, 2021 04:30 pm ET
Profound Medical to Participate in the 2021 Bloom Burton & Co. Virtual Healthcare Investor Conference
Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, announced today that...
Mar 03, 2021 07:00 am ET
Profound Medical Announces the Appointment of Cynthia Lavoie to its Board of Directors
Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, announced today the appointment of Cynthia...
Mar 02, 2021 04:02 pm ET
Profound Medical Announces Fourth Quarter and Full Year 2020 Financial Results
Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today reported financial...
Feb 25, 2021 04:30 pm ET
Profound Medical to Participate in March Virtual Investor Conferences
Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, announced today that management will...
Feb 11, 2021 04:30 pm ET
Profound Medical to Participate in the BTIG Virtual MedTech, Digital Health, Life Science and Diagnostic Tools Conference
Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, announced today that management will...
Feb 09, 2021 04:30 pm ET
Profound Medical to Release Fourth Quarter and Full Year 2020 Financial Results on March 2 – Conference Call to Follow
Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, will announce its fourth quarter and full...
Jan 05, 2021 04:30 pm ET
Profound Medical Announces Preliminary Unaudited Fourth Quarter and Full Year 2020 Revenues
Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today announced preliminary unaudited...
Dec 21, 2020 07:30 am ET
Profound Medical Signs Agreement with GE Healthcare to Expand Provider Access to TULSA-PRO®
Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), the only company to provide customizable, incision-free therapies which combine real-time Magnetic Resonance Imaging (“MRI”), thermal ultrasound and closed-loop...
Nov 30, 2020 08:00 am ET
Profound Medical Receives FDA HDE Approval for Sonalleve®
Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”) announced today that Sonalleve® has received U.S. Food and Drug Administration (“FDA”) approval under a Humanitarian Device Exemption (“HDE”) for the treatment of osteoid...
Nov 30, 2020 07:45 am ET
Profound Medical Announces Changes to its Board of Directors
Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), the only company to provide customizable, incision-free therapies which combine real-time Magnetic Resonance Imaging (“MRI”), thermal ultrasound and closed-loop...
Nov 10, 2020 04:30 pm ET
Profound Medical to Participate in November Virtual Investor Healthcare Conferences
Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), the only company to provide customizable, incision-free therapies which combine real-time Magnetic Resonance Imaging (“MRI”), thermal ultrasound and closed-loop...
Nov 05, 2020 04:02 pm ET
Profound Medical Announces Third Quarter 2020 Financial Results
Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), the only company to provide customizable, incision-free therapies which combine real-time Magnetic Resonance Imaging (“MRI”), thermal ultrasound and closed-loop...
Oct 15, 2020 04:30 pm ET
Profound Medical to Release Third Quarter 2020 Financial Results on November 5 – Conference Call to Follow
Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), the only company to provide customizable, incision-free therapies which combine real-time Magnetic Resonance Imaging (“MRI”), thermal ultrasound and closed-loop...
Sep 09, 2020 04:30 pm ET
Profound Medical to Present at the Cantor Virtual Global Healthcare Conference
Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), the only company to provide customizable, incision-free therapies which combine real-time Magnetic Resonance Imaging (“MRI”), thermal ultrasound and closed-loop...
Aug 10, 2020 08:00 am ET
Profound Medical Present at the Canaccord Genuity 40th Annual Growth Conference
Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), the only company to provide customizable, incision-free therapies which combine real-time Magnetic Resonance Imaging (“MRI”), thermal ultrasound and closed-loop...
Aug 06, 2020 04:02 pm ET
Profound Medical Announces Second Quarter 2020 Financial Results
Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), the only company to provide customizable, incision-free therapies which combine real-time Magnetic Resonance Imaging (“MRI”), thermal ultrasound and closed-loop...
Jul 22, 2020 08:00 am ET
Profound Medical to Release Second Quarter 2020 Financial Results on August 6 – Conference Call to Follow
Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), the only company to provide customizable, incision-free therapies which combine real-time Magnetic Resonance Imaging (“MRI”), thermal ultrasound and closed-loop...
Jul 21, 2020 12:35 pm ET
Profound Medical Announces Closing of Offering
Profound Medical Corp. (TSX:PRN; NASDAQ: PROF) (“Profound” or the “Company”) is pleased to announce that it has closed its previously-announced underwritten offering (the “Offering”) of common shares of the Company (the “Common Shares”) at a price...
Jul 15, 2020 08:58 pm ET
Profound Medical Announces Pricing of Offering of Common Shares
Profound Medical Corp. (TSX:PRN; NASDAQ: PROF) (“Profound” or the “Company”) is pleased to announce the pricing of an underwritten public offering (the “Offering”) of 2,758,621 common shares of the Company (the “Common Shares”), at a price of...
Jul 15, 2020 04:01 pm ET
Profound Medical Announces Proposed Offering of Common Shares
Profound Medical Corp. (TSX:PRN; NASDAQ: PROF) (“Profound” or the “Company”) is pleased to announce that it intends to file a preliminary prospectus supplement (the “Preliminary Supplement”) to its short form base shelf prospectus dated October 17,...
May 20, 2020 04:30 pm ET
Profound Medical Annual and Special Meeting of Shareholders Voting Results
Profound Medical Corp. (TSX: PRN; NASDAQ: PROF) (“Profound” or the “Company”) is pleased to announce the voting results from its Annual and Special Meeting of Shareholders that was held today (the “Meeting”). A total of 8,067,967 common shares,...
May 07, 2020 04:02 pm ET
Profound Medical Announces First Quarter 2020 Financial Results
Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), the only company to provide customizable, incision-free therapies which combine real-time Magnetic Resonance Imaging (“MRI”), thermal ultrasound and closed-loop...
Apr 16, 2020 04:30 pm ET
Profound Medical to Release First Quarter 2020 Financial Results on May 7 – Conference Call to Follow
Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company focused on customizable, incision-free therapies which combine real-time Magnetic Resonance Imaging (“MRI”), thermal ultrasound...
Mar 03, 2020 04:03 pm ET
Profound Medical Announces Fourth Quarter and Full Year 2019 Financial Results
Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company focused on customizable, incision-free therapies which combine real-time Magnetic Resonance Imaging (“MRI”), thermal ultrasound...
Feb 26, 2020 08:00 am ET
Profound Medical Participate in March Investor Healthcare Conferences
Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company focused on customizable, incision-free therapies which combine real-time Magnetic Resonance Imaging (“MRI”), thermal ultrasound...
Feb 12, 2020 08:00 am ET
Profound Medical to Release Fourth Quarter and Full Year 2019 Financial Results on March 3 – Conference Call to Follow
Profound Medical Corp. (TSX:PRN; NASDAQ:PROF) (“Profound” or the “Company”), a commercial-stage medical device company focused on customizable, incision-free therapies which combine real-time Magnetic Resonance Imaging (“MRI”), thermal ultrasound...
Feb 04, 2020 04:30 pm ET
Profound Medical Retires Bank Debt Ahead of Schedule
Profound Medical Corp. (TSX:PRN; NASDAQ:PROF) (“Profound” or the “Company”), a commercial-stage medical device company focused on customizable, incision-free therapies which combine real-time Magnetic Resonance Imaging (“MRI”), thermal ultrasound...
Jan 27, 2020 11:05 am ET
Profound Medical Announces Closing of Offering
Profound Medical Corp. (TSX:PRN; NASDAQ: PROF) (“Profound” or the “Company”) is pleased to announce that it has closed its previously-announced underwritten offering (the “Offering”) of common shares of the Company (the “Common Shares”) at a price...
Jan 22, 2020 08:55 am ET
Profound Medical Announces Pricing of Offering of Common Shares
Profound Medical Corp. (TSX:PRN; NASDAQ: PROF) (“Profound” or the “Company”) is pleased to announce the pricing of an underwritten public offering (the “Offering”) of 2,950,000 common shares of the Company (the “Common Shares”), at a price of...
Jan 22, 2020 08:09 am ET
IIROC Trade Resumption - PRN
TORONTO, Jan. 22, 2020 /CNW/ - Trading resumes in:
Jan 22, 2020 07:59 am ET
IIROC Trading Halt - PRN
TORONTO, Jan. 22, 2020 /CNW/ - The following issues have been halted by IIROC:
Jan 21, 2020 04:01 pm ET
Profound Medical Announces Proposed Offering of Common Shares
Profound Medical Corp. (TSX:PRN; NASDAQ: PROF) (“Profound” or the “Company”) is pleased to announce that it intends to file a preliminary prospectus supplement (the “Preliminary Supplement”) to its short form base shelf prospectus dated October 17,...
Jan 10, 2020 07:30 am ET
Profound Medical Announces Preliminary Unaudited Fourth Quarter and Full Year 2019 Revenues & Provides TULSA-PRO® U.S. Commercialization Update
Profound Medical Corp. (TSX:PRN; NASDAQ:PROF) (“Profound” or the “Company”), a commercial-stage medical device company focused on customizable, incision-free therapies which combine real-time Magnetic Resonance Imaging (“MRI”), thermal ultrasound...
Jan 10, 2020 06:02 am ET
Profound Medical and RadNet Sign the First-Ever U.S. Multi-Center Commercial Agreement for TULSA-PRO®
Profound Medical Corp. (TSX:PRN; NASDAQ:PROF) (“Profound” or the “Company”), a commercial-stage medical device company focused on customizable, incision-free therapies which combine real-time Magnetic Resonance Imaging (“MRI”), thermal ultrasound...
Dec 03, 2019 07:00 am ET
Profound Medical to Present at the First Annual BioTuesdays Pre-JPM Virtual Conference
Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), the only company to provide customizable, incision-free therapies which combine real-time Magnetic Resonance Imaging (“MRI”), thermal ultrasound and closed-loop...
Nov 25, 2019 04:15 pm ET
Profound Medical Announces Health Canada Approval of TULSA-PRO®
Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), the only company to provide customizable, incision-free therapies which combine real-time Magnetic Resonance Imaging (“MRI”), thermal ultrasound and closed-loop...
Nov 07, 2019 04:03 pm ET
Profound Medical Announces Third Quarter 2019 Financial Results
Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), the only company to provide customizable, incision-free therapies which combine real-time Magnetic Resonance Imaging (“MRI”), thermal ultrasound and closed-loop...
Oct 31, 2019 11:09 am ET
Profound Medical Corp. Opens the Market
TORONTO, Oct. 31, 2019 /CNW/ - Arun Menawat, Chief Executive Officer, Profound Medical Corp. (PRN), joined Dani Lipkin, Innovation Sector Head, Capital Formation, Toronto Stock Exchange and TSX Venture Exchange, to open the market. Profound Medical develops customizable, incision-free therapies, which combine real-time Magnetic Resonance (MR) imaging, thermal ultrasound and closed-loop temperature feedback control for the radiation-free ablation of diseased tissue. Profound Medical Corp. graduated and commenced trading on Toronto Stock Exchange on July 13, 2018.
Oct 31, 2019 08:30 am ET
Profound to Participate in November Investor Healthcare Conferences
Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), the only company to provide customizable, incision-free therapies which combine real-time Magnetic Resonance Imaging (“MRI”), thermal ultrasound and closed-loop...
Oct 28, 2019 04:15 pm ET
Profound Medical Announces Nasdaq Listing
Profound Medical Corp. (TSX:PRN; OTCQX:PRFMD) (“Profound” or the “Company”) today announced that The Nasdaq Stock Market LLC (“Nasdaq”) has certified the Company’s common shares for listing on the Nasdaq Capital Market. Profound’s common shares are...
Oct 24, 2019 04:30 pm ET
Profound Medical to Release Third Quarter 2019 Financial Results on November 7 – Conference Call to Follow
Profound Medical Corp. (TSX:PRN; OTCQX:PRMFD) (“Profound” or the “Company”), the only company to provide customizable, incision-free therapies which combine real-time Magnetic Resonance Imaging (“MRI”), thermal ultrasound and closed-loop...
Oct 11, 2019 11:00 am ET
Profound Medical Corp. Announces Share Consolidation in Connection With Proposed Nasdaq Listing
Profound Medical Corp. (TSX: PRN; OTCQX: PRFMF) (“Profound” or the “Company”) is pleased to announce that today it implemented a consolidation (the “Consolidation”) of its issued and outstanding common shares (“Common Shares”) on the basis of one...
Sep 23, 2019 05:00 pm ET
Profound Medical Proposes New MJDS Registration for its Proposed U.S. Listing
Profound Medical Corp. (TSX:PRN; OTCQX:PRFMF) (“Profound” or the “Company”) is pleased to announce that it proposes to file a new registration statement under the Multijurisdictional Disclosure System (the “MJDS”) of the U.S. Securities and...
Sep 20, 2019 09:13 am ET
Profound Medical Announces Closing of Offerings
Profound Medical Corp. (TSX:PRN; OTCQX:PRFMF) (“Profound” or the “Company”) is pleased to announce that it has closed its previously-announced offering of units of the Company (the “Units”) in all provinces of Canada, other than Quebec (the...
Sep 13, 2019 09:42 am ET
Profound Medical Announces Pricing of Offerings
Profound Medical Corp. (TSX:PRN; OTCQX:PRFMF) (“Profound” or the “Company”) is pleased to announce the pricing of its previously-announced marketed offering of units of the Company (the “Units”) in all provinces of Canada, other than Québec (the...
Sep 12, 2019 04:50 pm ET
Profound Medical Announces Proposed Offerings of Units
/NOT FOR DISTRIBUTION IN THE UNITED STATES OR OVER UNITED STATES WIRE SERVICES/
Sep 12, 2019 04:48 pm ET
Profound Medical Announces Proposed Offerings of Units
Profound Medical Corp. (TSX:PRN; OTCQX:PRFMF) (“Profound” or the “Company”) is pleased to announce that it intends to file a prospectus supplement to its short form base shelf prospectus dated September 19, 2018 relating to a proposed marketed...
Aug 16, 2019 07:00 am ET
Profound Medical Receives U.S. FDA 510(k) Clearance for TULSA-PRO®
Profound Medical Corp. (TSX:PRN; OTCQX:PRFMF) (“Profound” or the “Company today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (“FDA”) to market TULSA-PRO® for ablation of prostate tissue. TULSA-PRO® is...
Aug 15, 2019 08:30 am ET
Accomplished Financial Executive, Steve Forte, Joins Profound Medical’s Board
Profound Medical Corp. (TSX:PRN; OTCQX:PRFMF) (“Profound” or the “Company”), the only company to provide customizable, incision-free therapies which combine real-time Magnetic Resonance Imaging (“MRI”), thermal ultrasound and closed-loop...
Aug 14, 2019 04:01 pm ET
Profound Medical Announces Second Quarter 2019 Financial Results
Profound Medical Corp. (TSX:PRN; OTCQX:PRFMF) (“Profound” or the “Company”), the only company to provide customizable, incision-free therapies which combine real-time Magnetic Resonance Imaging (“MRI”), thermal ultrasound and closed-loop...
Jul 31, 2019 04:30 pm ET
Profound Medical to Present at the Canaccord Genuity 39th Annual Growth Conference
Profound Medical Corp. (TSX:PRN; OTCQX:PRFMF) (“Profound” or the “Company”), the only company to provide customizable, incision-free therapies which combine real-time Magnetic Resonance Imaging (“MRI”), thermal ultrasound and closed-loop...
Jul 30, 2019 04:30 pm ET
Profound Medical to Release Second Quarter 2019 Financial Results on August 14 – Conference Call to Follow
Profound Medical Corp. (TSX:PRN; OTCQX:PRFMF) (“Profound” or the “Company”), the only company to provide customizable, incision-free therapies which combine real-time Magnetic Resonance Imaging (“MRI”), thermal ultrasound and closed-loop...
Jul 09, 2019 04:30 pm ET
Profound Medical Sells First TULSA-PRO® System in Japan
Profound Medical Corp. (TSX:PRN; OTCQX:PRFMF) (“Profound” or the “Company”), the only company to provide customizable, incision-free therapies which combine real-time Magnetic Resonance Imaging (“MRI”), thermal ultrasound and closed-loop...
Jun 13, 2019 05:10 pm ET
Profound Medical Annual and Special Meeting of Shareholders Voting Results
Profound Medical Corp. (TSX:PRN; OTCQX:PRFMF) (“Profound” or the “Company”), the only company to provide customizable, incision-free therapies which combine real-time Magnetic Resonance Imaging (“MRI”), thermal ultrasound and closed-loop...
May 06, 2019 04:02 pm ET
Profound Medical Announces First Quarter 2019 Financial Results
Profound Medical Corp. (TSX:PRN; OTCQX:PRFMF) (“Profound” or the “Company”), the only company to provide customizable, incision-free therapies which combine real-time Magnetic Resonance Imaging (“MRI”), thermal ultrasound and closed-loop...
Apr 23, 2019 08:00 am ET
Profound Medical to Present at the 2019 Bloom Burton & Co. Healthcare Investor Conference
Profound Medical Corp. (TSX:PRN; OTCQX:PRFMF) (“Profound” or the “Company”), the only company to provide customizable, incision-free therapies which combine real-time Magnetic Resonance Imaging (“MRI”), thermal ultrasound and closed-loop...
Apr 17, 2019 04:30 pm ET
Profound Medical to Release First Quarter 2019 Financial Results on May 6 – Conference Call to Follow
Profound Medical Corp. (TSX:PRN; OTCQX:PRFMF) (“Profound” or the “Company”), the only company to provide customizable, incision-free therapies which combine real-time Magnetic Resonance Imaging (“MRI”), thermal ultrasound and closed-loop...
Apr 16, 2019 08:00 am ET
Profound Medical Announces First-of-its-Kind TULSA-PRO® Installation
Profound Medical Corp. (TSX:PRN; OTCQX:PRFMF) (“Profound” or the “Company”), the only company to provide customizable, incision-free therapies which combine real-time Magnetic Resonance imaging (“MRI”), thermal ultrasound and closed-loop...
Apr 15, 2019 07:02 am ET
Foundation Chairman Shares Focused Ultrasound Growth at Inaugural Global Investor Conference
CHARLOTTESVILLE, Va., April 15, 2019 /PRNewswire/ -- Focused Ultrasound Foundation Chairman Neal F. Kassell, MD, was the keynote speaker at Analyst & Investor Day at the University Club in New York, NY, on April 11. The event was a first-of-its-kind gathering in the field of focused ultrasound and included key researchers, clinicians, financial analysts and institutional investors from around the world. The meeting was hosted by Profound Medical Corp., which provides a therapeutic platform combining real-time magnetic resonance imaging and ultrasound technology for the precise, incision-
Apr 08, 2019 08:00 am ET
Profound Medical Analyst & Investor Day Agenda
Profound Medical Corp. (TSX:PRN; OTCQX:PRFMF) (“Profound” or the “Company”), the only company to provide customizable, incision-free therapies which combine real-time Magnetic Resonance Imaging (“MRI”), thermal ultrasound and closed-loop...
Apr 04, 2019 07:45 pm ET
Profound Medical Announces Positive Topline Results from TACT Pivotal Clinical Trial of TULSA-PRO® in Patients with Prostate Cancer
Profound Medical Corp. (TSX:PRN; OTCQX:PRFMF) (“Profound” or the “Company”), the only company to provide customizable, incision-free therapies which combine real-time Magnetic Resonance imaging (“MRI”), thermal ultrasound and closed-loop...
Mar 07, 2019 04:02 pm ET
Profound Medical Announces Fourth Quarter and Full Year 2018 Financial Results
Profound Medical Corp. (TSX:PRN; OTCQX:PRFMF) (“Profound” or the “Company”), the only company to provide a therapeutics platform that provides the precision of real-time Magnetic Resonance (“MR”) imaging combined with the safety and ablation power...
Mar 05, 2019 08:00 am ET
Profound Medical to Present at the Cowen and Company 39th Annual Health Care Conference
Profound Medical Corp. (TSX:PRN; OTCQX:PRFMF) (“Profound” or the “Company”), the only company to provide a therapeutics platform that combines real-time Magnetic Resonance (“MR”) imaging and ultrasound technology for the precise, incision-free...
Feb 28, 2019 08:30 am ET
Save the Date: Profound Medical to Host Inaugural Analyst & Investor Day on April 11
Profound Medical Corp. (TSX:PRN; OTCQX:PRFMF) (“Profound” or the “Company”), the only company to provide a therapeutics platform that combines real-time Magnetic Resonance (“MR”) imaging and ultrasound technology for the precise, incision-free...
Feb 21, 2019 04:30 pm ET
Profound Medical to Release Fourth Quarter and Full Year 2018 Financial Results on March 7 – Conference Call to Follow
Profound Medical Corp. (TSX:PRN; OTCQX:PRFMF) (“Profound” or the “Company”), the only company to provide a therapeutics platform that combines real-time Magnetic Resonance (“MR”) imaging and ultrasound technology for the precise, incision-free...
Feb 20, 2019 04:30 pm ET
Profound Medical to Participate in the 2019 BTIG MedTech, Life Science & Diagnostic Tools Conference
Profound Medical Corp. (TSX:PRN; OTCQX:PRFMF) (“Profound” or the “Company”), the only company to provide a therapeutics platform that combines real-time Magnetic Resonance (“MR”) imaging and ultrasound technology for the precise, incision-free...
Jan 03, 2019 04:30 pm ET
Profound Medical Announces Preliminary Unaudited Fourth Quarter 2018 Revenues
Profound Medical Corp. (TSX:PRN; OTCQX:PRFMF) (“Profound” or the “Company”), the only company to provide a therapeutics platform that combines real-time Magnetic Resonance (“MR”) imaging and ultrasound technology for the precise, incision-free...
Dec 14, 2018 08:00 am ET
Profound Medical Announces Changes to Commercial Organization
Profound Medical Corp. (TSX:PRN; OTCQX:PRFMF) (“Profound” or the “Company”), the only company to provide a therapeutics platform that provides the precision of real-time Magnetic Resonance (“MR”) imaging combined with the safety and ablation power...
Nov 08, 2018 04:01 pm ET
Profound Medical Announces Third Quarter 2018 Financial Results
Profound Medical Corp. (TSX:PRN; OTCQX:PRFMF) (“Profound” or the “Company”), the only company to provide a therapeutics platform that provides the precision of real-time Magnetic Resonance (“MR”) imaging combined with the safety and ablation power...
Nov 08, 2018 08:15 am ET
Profound Medical to Present at the 2018 Canaccord Genuity Medical Technologies & Diagnostics Forum
TORONTO, ON / ACCESSWIRE / November 8, 2018 / Profound Medical Corp. (TSX: PRN; OTCQX: PRFMF) ("Profound" or the "Company"), the only company to provide a therapeutics platform that provides the precision of real-time Magnetic Resonance ("MR") imaging combined with the safety and ablation power of directional and focused ultrasound technology for the incision-free ablation of diseased tissue, announced today that management will present an update on the Company's business at the 2018 Canaccord Genuity Medical Technologies & Diagnostics Forum o
Nov 07, 2018 08:30 am ET
Profound Medical to Present at the Stifel 2018 Healthcare Conference
Profound Medical Corp. (TSX:PRN; OTCQX:PRFMF) (“Profound” or the “Company”), the only company to provide a therapeutics platform that provides the precision of real-time Magnetic Resonance (“MR”) imaging combined with the safety and ablation power...
Oct 30, 2018 04:30 pm ET
Profound Medical to Release Third Quarter 2018 Financial Results on November 8 – Conference Call to Follow
Profound Medical Corp. (TSX:PRN; OTCQX:PRFMF) (“Profound” or the “Company”), the only company to provide a therapeutics platform that provides the precision of real-time Magnetic Resonance (“MR”) imaging combined with the safety and ablation power...
Sep 18, 2018 04:30 pm ET
3-Year Clinical Outcomes and BPH Subgroup Analysis of Profound Medical’s Phase I Clinical Trial to be Included in Presentation at DGU 2018
Profound Medical Corp. (TSX:PRN; OTCQX:PRFMF) (“Profound” or the “Company”), the only company to provide a therapeutics platform that provides the precision of real-time Magnetic Resonance (“MR”) imaging combined with the safety and ablation power...
Sep 06, 2018 04:10 pm ET
Profound Medical Files Preliminary Base Shelf Prospectus
Profound Medical Corp. (TSX:PRN; OTCQX:PRFMF) (“Profound” or the “Company”) announced today that it has filed and obtained a receipt for a preliminary short form base shelf prospectus (“Shelf Prospectus”) with the securities commissions in each of...
Aug 14, 2018 04:05 pm ET
Profound Medical Announces Second Quarter 2018 Financial Results
Profound Medical Corp. (TSX:PRN; OTCQX:PRFMF) (“Profound” or the “Company”), the only company to provide a therapeutics platform that provides the precision of real-time Magnetic Resonance (“MR”) imaging combined with the safety and ablation power...
Aug 02, 2018 04:30 pm ET
Profound Medical to Release Second Quarter 2018 Financial Results on August 14 – Conference Call to Follow
Profound Medical Corp. (TSX:PRN; OTCQX:PRFMF) (“Profound” or the “Company”), the only company to provide a therapeutics platform that provides the precision of real-time Magnetic Resonance (“MR”) imaging combined with the safety and ablation power...
Jul 31, 2018 04:30 pm ET
Profound Medical to Present at the Canaccord Genuity 38th Annual Growth Conference
Profound Medical Corp. (TSX:PRN; OTCQX:PRFMF) (“Profound” or the “Company”), the only company to provide a therapeutics platform that provides the precision of real-time Magnetic Resonance (“MR”) imaging combined with the safety and ablation power...
Jul 31, 2018 08:30 am ET
Profound Medical Announces Term Loan Agreement with CIBC Innovation Banking
Profound Medical Corp. (“Profound” or the “Company”) (TSX:PRN) (OTCQX:PRFMF) today announced that it has entered into a term loan agreement (the “Agreement”) with the CIBC Innovation Banking (“CIBC”), which provides Profound with up to $18.75...
Jul 11, 2018 10:10 am ET
Profound Medical Corp. Announces Graduation to Toronto Stock Exchange
Profound Medical Corp. (TSX-V:PRN) (OTCQX:PRFMF) (“Profound” or the “Company”), the only company to provide a therapeutics platform that provides the precision of real-time Magnetic Resonance (“MR”) imaging combined with the safety and ablation...
Jun 14, 2018 04:30 pm ET
Profound Medical Announces Annual Meeting of Shareholders Voting Results; Welcomes Two Industry Veterans as Independent Directors to its Board
Profound Medical Corp. (“Profound” or the “Company”) (TSXV: PRN) (OTCQX:PRFMF) is pleased to announce the results of the votes on the matters considered at its Annual Meeting of Shareholders that was held today. A total of 55,264,907 common...
May 21, 2018 11:20 am ET
Initial Data from Profound Medical’s TACT Pivotal Clinical Trial Presented at AUA 2018
Profound Medical Corp. (TSX-V:PRN) (OTCQX:PRFMF) (“Profound” or the “Company”), the only company to provide a therapeutics platform that provides the precision of real-time Magnetic Resonance (“MR”) imaging combined with the safety and ablation...
May 10, 2018 04:02 pm ET
Profound Medical Corp. Announces First Quarter 2018 Financial Results
Profound Medical Corp. (TSX-V:PRN) (OTCQX:PRFMF) (“Profound” or the “Company”), the only company to provide a therapeutics platform that provides the precision of real-time Magnetic Resonance (“MR”) imaging combined with the safety and ablation...
May 09, 2018 04:30 pm ET
Profound Medical Corp. Announces Chinese Food and Drug Administration Approval for Sonalleve®
Profound Medical Corp. (TSX-V:PRN) (OTCQX:PRFMF) (“Profound” or the “Company”), the only company to provide a therapeutics platform that provides the precision of real-time Magnetic Resonance (“MR”) imaging combined with the safety and ablation...
May 02, 2018 08:00 am ET
Profound Medical to Release First Quarter 2018 Financial Results on May 10, 2018 – Conference Call to Follow
TORONTO, May 02, 2018 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX-V:PRN) (OTCQX:PRFMF) (“Profound” or the “Company”), the only company to offer a therapeutic platform that provides the precision of real-time MR imaging combined with the safety and accuracy...
May 01, 2018 08:30 am ET
Profound Medical Further Strengthens Management Team with Appointment of Aaron Davidson as Chief Financial Officer and Senior Vice-President of Corporate Development
TORONTO, May 01, 2018 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX-V:PRN) (OTCQX:PRFMF) (“Profound” or the “Company”), the only company to provide a therapeutics platform that provides the precision of real-time Magnetic Resonance (“MR”) imaging combined with the safety...
Apr 25, 2018 08:30 am ET
Profound Medical to Present at the 2018 Bloom Burton & Co. Healthcare Investor Conference
TORONTO, April 25, 2018 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX-V:PRN) (OTCQX:PRFMF) (“Profound” or the “Company”), the only company to provide a therapeutics platform that provides the precision of real-time Magnetic Resonance (“MR”) imaging combined with the safety...
Apr 23, 2018 08:30 am ET
Accomplished International Medical Device Industry Executive, Ian Heynen, to Lead Profound Medical’s Sales and Marketing Function
TORONTO, April 23, 2018 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX-V:PRN) (OTCQX:PRFMF) (“Profound” or the “Company”), the only company to provide a therapeutics platform that provides the precision of real-time Magnetic Resonance (“MR”) imaging combined with the safety...
Mar 26, 2018 04:01 pm ET
Profound Medical Corp. Announces Fourth Quarter and Full Year 2017 Financial Results
TORONTO, March 26, 2018 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX-V:PRN) (OTCQX:PRFMF) (“Profound” or the “Company”), the only company to provide a therapeutics platform that provides the precision of real-time Magnetic Resonance (“MR”) imaging combined with the safety...
Mar 20, 2018 09:30 am ET
Profound Medical Corp. Announces Closing of Bought Deal Financing
THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES.
Mar 09, 2018 04:45 pm ET
Profound Medical to Release Fourth Quarter and Full Year 2017 Financial Results on March 26, 2018 – Conference Call to Follow
TORONTO, March 09, 2018 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX-V:PRN) (OTCQX:PRFMF) (“Profound” or the “Company”), the only company to offer a therapeutic platform that provides the precision of real-time MR imaging combined with the safety and accuracy...
Feb 28, 2018 07:30 am ET
Profound Medical Corp. Upsizes Previously Announced Bought Deal Financing
/THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES./
Feb 27, 2018 03:23 pm ET
Profound Medical Corp. Announces $20 Million Bought Deal Financing
/THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES./
Feb 26, 2018 08:00 am ET
Profound Medical to Participate in 2018 BTIG Healthcare Conference
TORONTO, Feb. 26, 2018 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX-V:PRN) (OTCQX:PRFMF) (“Profound” or the “Company”), the only company to offer a therapeutic platform that provides the precision of real-time MR imaging combined with the safety and accuracy...
Jan 31, 2018 08:00 am ET
Profound Medical Corp. Announces Completion of Patient Enrollment in TACT Pivotal Clinical Trial
TORONTO, Jan. 31, 2018 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX-V:PRN) (OTCQX:PRFMF) (“Profound” or the “Company”), the only company to offer a therapeutic platform that provides the precision of real-time MR imaging combined with the safety and accuracy...
Jan 08, 2018 07:30 am ET
Profound Medical Corp. Announces Preliminary Fourth Quarter 2017 Revenue and Provides Progress Update on TACT Pivotal Trial Patient Enrollment
TORONTO, Jan. 08, 2018 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX-V:PRN) (OTCQX:PRFMF) (“Profound” or the “Company”), the only company to provide a therapeutics platform that provides the precision of real-time MR imaging combined with the safety and ablation power...
Nov 14, 2017 04:30 pm ET
Profound Medical Corp. to Present at the 29th Annual Piper Jaffray Healthcare Conference
TORONTO, Nov. 14, 2017 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX-V:PRN) (OTCQX:PRFMF) (“Profound” or the “Company”), the only company to provide a therapeutics platform that provides the precision of real-time MR imaging combined with the safety and ablation...
Nov 07, 2017 04:45 pm ET
Profound Medical Corp. Announces Third Quarter 2017 Financial Results
TORONTO, Nov. 07, 2017 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX-V:PRN) (OTCQX:PRFMF) (“Profound” or the “Company”), the only company to provide a therapeutics platform that provides the precision of real-time Magnetic Resonance (“MR”) imaging combined with the safety and ablation power of directional (inside-out) and focused (outside-in) ultrasound technology for the incision-free ablation of diseased tissue, today reported financial results for the three and nine months ended September 30, 2017. All amounts, unless specified otherwise, are expressed in Canadian dollars and are pres...
Nov 07, 2017 04:45 pm ET
Profound Medical Corp. Announces Third Quarter 2017 Financial Results
TORONTO, Nov. 07, 2017 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX-V:PRN) (OTCQX:PRFMF) (“Profound” or the “Company”), the only company to provide a therapeutics platform that provides the precision of real-time Magnetic Resonance (“MR”) imaging combined with the safety...
Nov 06, 2017 08:30 am ET
Profound Medical Corp. Announces Expanded Clinical Use of TULSA-PRO® in Prostate Care to Include BPH
TORONTO, Nov. 06, 2017 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX-V:PRN) (OTCQX:PRFMF) (“Profound” or the “Company”), the only company to provide a therapeutics platform that provides the precision of real-time MR imaging combined with the safety and ablation...
Sep 20, 2017 04:18 pm ET
Profound Medical Corp. Announces Closing of $10 Million “Bought Deal” Financing
NOT FOR DISTRIBUTION TO UNITED STATES WIRE SERVICES OR DISSEMINATION IN THE UNITED STATES...
Aug 23, 2017 04:01 pm ET
Profound Medical Announces Second Quarter 2017 Financial Results
TORONTO, Aug. 23, 2017 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSXV:PRN) (OTCQX:PRFMF) (“Profound” or the “Company”), the only company to provide a therapeutic platform that provides the precision of real-time MR imaging combined with the safety and ablation power of directional (inside-out) and focused (outside-in) ultrasound technology for the incision-free ablation of diseased tissue, today reported financial results for the three and six months ended June 30, 2017. All amounts, unless specified otherwise, are expressed in Canadian dollars and are presented in accordance with Internat...
Jul 31, 2017 05:10 pm ET
Profound Medical Corp. Completes Acquisition of Royal Philips’ Sonalleve MR-HIFU Business
TORONTO, July 31, 2017 (GLOBE NEWSWIRE) -- With reference to its press release dated June 30, 2017, Profound Medical Corp. (TSXV:PRN) (OTCQX:PRFMF) (“Profound”) announced today that all closing conditions have been satisfied and it has completed the acquisition of Royal Philips’ (NYSE:PHG) (AEX:PHIA) (“Philips”) Sonalleve MR-HIFU business....
Jun 30, 2017 11:03 am ET
IIROC Trading Resumption - PRN
VANCOUVER, June 30, 2017 /CNW/ - Trading resumes in:
Jun 30, 2017 08:49 am ET
IIROC Trading Halt - FMR; PRN
VANCOUVER, June 30, 2017 /CNW/ - The following issues have been halted by IIROC:
May 24, 2017 04:30 pm ET
Profound Medical Corp. Announces Annual Meeting of Shareholders Voting Results
TORONTO, May 24, 2017 (GLOBE NEWSWIRE) -- Profound Medical Corp. (“Profound” or the “Company”) (TSXV:PRN) (OTCQX:PRFMF) is pleased to announce the results of the votes on the matters considered at its Annual Meeting of Shareholders that was held yesterday. A total of 30,091,325 common shares, representing 54.37% of the shares outstanding, were represented in person and by proxy at the meeting....
May 15, 2017 09:30 am ET
Profound Medical Corp. Presentation Now Available for On-Demand Viewing
Company invites individual and institutional investors as well as advisors to log-on to VirtualInvestorConferences.com to view presentation
May 15, 2017 09:30 am ET
Profound Medical Corp. Presentation Now Available for On-Demand Viewing
Company invites individual and institutional investors as well as advisors to log-on to VirtualInvestorConferences.com to view presentation
May 09, 2017 04:01 pm ET
Profound Medical Corp. Announces First Quarter 2017 Financial Results
TORONTO, May 09, 2017 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSXV:PRN) (OTCQX:PRFMF) (“Profound” or the “Company”) an emerging medical device company focused on prostate care, today reported financial results for the three months ended March 31, 2017. All amounts, unless specified otherwise, are expressed in Canadian dollars and are presented in accordance with International Financial Reporting Standards as issued by the International Accounting Standards Board, applicable to the preparation of interim financial statements, including IAS-34, Interim Financial Reporting....
May 08, 2017 09:30 am ET
Profound Medical Corp. to Webcast, Live, at VirtualInvestorConferences.com May 11
Company invites individual and institutional investors as well as advisors to attend interactive real-time virtual VirtualInvestorConferences.com
May 08, 2017 09:30 am ET
Profound Medical Corp. to Webcast, Live, at VirtualInvestorConferences.com May 11
Company invites individual and institutional investors as well as advisors to attend interactive real-time virtual VirtualInvestorConferences.com
May 04, 2017 09:30 am ET
OTC Markets Group Announces Agenda for May 11th OTCQX International Virtual Investor Conference
NEW YORK, May 4, 2017 /CNW/ -- OTC Markets Group Inc. (OTCQX: OTCM), operator of financial markets for 10,000 U.S. and global securities, today announced the agenda for its OTCQX International Virtual Investor Conference taking place on Thursday, May 11th, beginning at 9:00 a.m. Eastern time.
May 04, 2017 09:30 am ET
OTC Markets Group Announces Agenda for May 11th OTCQX International Virtual Investor Conference
NEW YORK, May 4, 2017 /PRNewswire/ -- OTC Markets Group Inc. (OTCQX: OTCM), operator of financial markets for 10,000 U.S. and global securities, today announced the agenda for its OTCQX International Virtual Investor Conference taking place on Thursday, May 11th, beginning at 9:00 a.m. Eastern time.
May 03, 2017 04:30 pm ET
Profound Medical to Present at the CIBC Technology & Innovation Conference 5.0
TORONTO, May 03, 2017 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX-V:PRN) (OTCQX:PRFMF) “Profound” or the “Company”), an emerging medical device company focused on prostate care, today announced that its CEO, Arun Menawat, will present an update on the Company's business at the CIBC Technology & Innovation Conference 5.0 on Tuesday, May 16, 2017, at 3:25 p.m. Eastern Time. The conference will be held at the Westin Harbour Castle in Toronto, ON....
Apr 25, 2017 04:30 pm ET
Profound Medical Corp. to Release First Quarter 2017 Financial Results on May 9, 2017 – Conference Call to Follow
TORONTO, April 25, 2017 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX-V:PRN) (OTCQX:PRFMF) (“Profound” or the “Company”), an emerging medical device company focused on prostate care, will announce its first quarter 2017 financial results after market close on Tuesday, May 9, 2017....
Apr 18, 2017 08:00 am ET
Profound Medical Corp. Obtains DTC Eligibility for its Common Shares in the U.S.
TORONTO, April 18, 2017 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX-V:PRN) (OTCQX:PRFMF) (“Profound” or the “Company”) an emerging medical device company focused on prostate care, announced today that it has secured Depository Trust Company (“DTC”) eligibility for its common shares listed on the OTCQX....
Mar 27, 2017 08:00 am ET
Profound Medical Corp. Announces First Paid Procedure Using TULSA-PRO® System
TORONTO, March 27, 2017 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSXV:PRN) (OTCQX:PRFMF) (“Profound” or the “Company”), an emerging medical device company focused on prostate care, today announced that the first TULSA-PRO® patient paid procedure has been successfully conducted at the ALTA Klinik (“ALTA”) in Bielefeld, Germany under the supervision of Dr. Agron Lumiani....
Mar 13, 2017 08:00 am ET
OTC Markets Group Welcomes Profound Medical to OTCQX
NEW YORK, March 13, 2017 /PRNewswire/ -- OTC Markets Group Inc. (OTCQX: OTCM), operator of financial markets for 10,000 U.S. and global securities, today announced Profound Medical Corp. (TSX-V: PRN; OTCQX: PRFMF), an emerging medical device company focused on prostate care, has qualified to trade on the OTCQX® Best Market. Profound Medical upgraded to OTCQX from the Pink® market.
Mar 09, 2017 04:30 pm ET
Profound Medical Corp. to Begin Trading on OTCQX on March 13, 2017
TORONTO, March 09, 2017 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX-V:PRN) (“Profound” or the “Company”), an emerging medical device company focused on prostate care, is pleased to announce that its common shares will be eligible for trading on the OTCQX® Best Market under the symbol “PRFMF”, effective with the open of business on March 13, 2017....
Feb 21, 2017 04:30 pm ET
Profound Medical Corp. to Release Fourth Quarter and Full Year 2016 Financial Results on March 6, 2017 – Conference Call to Follow
TORONTO, Feb. 21, 2017 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX-V:PRN) (“Profound” or the “Company”), an emerging medical device company focused on prostate care, will announce its fourth quarter and full 2016 financial results after market close on Monday, March 6, 2017....
Feb 14, 2017 04:30 pm ET
Profound Medical to Participate in 2017 BTIG Medical Technology, Life Science and Diagnostic Tools Conference
TORONTO, Feb. 14, 2017 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX-V:PRN) (“Profound” or the “Company”), an emerging medical device company focused on prostate care, today announced that its management team is scheduled to participate in BTIG’s 2017 Medical Technology, Life Science and Diagnostic Tools Conference on March 1, 2017 in Snowbird, Utah. ...
Jan 26, 2017 06:26 pm ET
Profound Medical Announces Special Meeting of Shareholders Voting Results
TORONTO, Jan. 26, 2017 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX-V:PRN) (“Profound” or the “Company”), an emerging medical device company focused on prostate care, is pleased to announce the results of the vote on the matters considered at its Special Meeting of Shareholders that was held on January 26, 2017. A total of 20,155,571 common shares held by disinterested shareholders, representing 36.44% of the issued and outstanding common shares, were represented in person and by proxy at the meeting....
Jan 17, 2017 04:30 pm ET
Profound Medical Announces Appointment of Kenneth Galbraith to its Board of Directors
TORONTO, Jan. 17, 2017 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX-V:PRN) (“Profound” or the “Company”), an emerging medical device company focused on prostate care, today announced the appointment of Kenneth Galbraith to its Board of Directors. In connection with Mr. Galbraith’s appointment, Steven Plymale has resigned from the Company’s Board, but remains President and Chief Operating Officer....
Jan 17, 2017 08:00 am ET
XOR-Labs adds experienced medical device executive Steven Plymale to Board of Directors
XOR-Labs Toronto Inc. (XOR), a spin-off from Toronto General Hospital at University Health Network the world's leading center for lung transplantation and a MaRS Innovation company, today announced the appointment of Steven Plymale as an Independent...
Nov 16, 2016 04:01 pm ET
Profound Medical Corp. Announces Third Quarter 2016 Financial Results
TORONTO, Nov. 16, 2016 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX-V:PRN) (“Profound” or the “Company”), an emerging medical device company focused on prostate care, today reported financial results for the three months ended September 30, 2016. All amounts, unless specified otherwise, are expressed in Canadian dollars and are presented in accordance with International Financial Reporting Standards....
Nov 03, 2016 04:30 pm ET
Profound Medical Corp. To Present at the 2016 Canaccord Genuity Medical Technologies & Diagnostics Forum
TORONTO, Nov. 03, 2016 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX-V:PRN) (“Profound” or the “Company”), an emerging medical device company focused on prostate care, announced today that its CEO, Arun Menawat, will present an update on the Company's business at the Canaccord Genuity Medical Technologies & Diagnostics Forum on Thursday, November 17, 2016, at 1:00 p.m. Eastern Time. The conference will be held at the Westin Grand Central in New York City....
Nov 01, 2016 04:30 pm ET
Profound Medical Corp. To Present at the Stifel 2016 Healthcare Conference
TORONTO, Nov. 01, 2016 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX-V:PRN) (“Profound” or the “Company”), an emerging medical device company focused on prostate care, announced today that its CEO, Arun Menawat, will present an update on the Company's business at the Stifel 2016 Healthcare Conference on Tuesday, November 15, 2016, at 1:30 p.m. Eastern Time. The conference will be held at the Lotte New York Palace Hotel in New York City....
Oct 26, 2016 04:30 pm ET
Profound Medical Corp. to Release Third Quarter 2016 Financial Results on November 16, 2016 – Conference Call to Follow
TORONTO, Oct. 26, 2016 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX-V:PRN) (“Profound” or the “Company”), an emerging medical device company focused on prostate care, will announce financial results for the third quarter of 2016 after market close on Wednesday, November 16, 2016....
Oct 17, 2016 08:15 am ET
Profound Medical Corp. Announces $17.4 Million Bought Deal Financing
THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES....
Oct 17, 2016 07:54 am ET
Profound Medical Corp. Announces $17.4 Million Bought Deal Financing
THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES.
Profound Medical Corp. ("Profound" or "Company") (TSX...
Sep 22, 2016 08:00 am ET
Profound Medical Corp. Announces First Patient Treated in TACT Pivotal Clinical Trial at Vanderbilt University Medical Center
TORONTO, Sept. 22, 2016 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSXV:PRN) (“Profound” or the “Company”) a medical device company focused on prostate care, today announced that the first patient has been treated in the TACT Pivotal Clinical Trial at Vanderbilt University Medical Center in Nashville, TN....
Aug 18, 2016 04:40 pm ET
Profound Medical Corp. Announces Second Quarter 2016 Financial Results
TORONTO, Aug. 18, 2016 (GLOBE NEWSWIRE) -- Profound Medical Corp. (“Profound” or the “Company”) (TSXV:PRN), an emerging medical device company focused on prostate cancer care, today reported financial results for the three months ended June 30, 2016. All amounts, unless specified otherwise, are expressed in Canadian dollars and are presented in accordance with International Financial Reporting Standards....
Aug 15, 2016 04:10 pm ET
Profound Medical Corp. Announces Senior Management Changes to Support Global Growth Strategy
TORONTO, Aug. 15, 2016 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSXV:PRN) (“Profound” or the “Company”), an emerging medical device company focused on prostate cancer care, today announced the appointment of Arun Menawat, Ph.D. as its new Chief Executive Officer. Steven Plymale, the Company’s current CEO, will transition to President and Chief Operating Officer....
Disclaimer :: Use of this site is subject to, and your continued use
constitutes your express agreement to be bound by, our Legal and Terms of Use. Any commercial use of this site is
strictly prohibited. Canadianinsider.com is operated by INK Research Corp (INK). INK provides general information.
INK has made all reasonable efforts to ensure that all information provided is accurate at the time of inclusion;
however, there may be errors. INK makes no guarantee of accuracy or completeness. All information and opinion
expressed herein is subject to change without notice. Read more...Insider information is based on filings made on the System
for Electronic Disclosure for Insiders (SEDI®). Data is provided “as is” and by using this site
you acknowledge that the information which comprises the data is filed by or on behalf of the SEDI filers or other
parties legally required or permitted to do so. Filings may at any time contain errors and by using this site you
acknowledge this fact. INK is not an investment advisory service, a financial planner, an investment advisor nor a
securities advisor. INK does not purport to tell people, or suggest to people, what they should buy or sell for
themselves. Opinions and recommendations contained herein should not be construed as investment advice. Do not
assume that any recommendations, insights, charts, theories, or philosophies will ensure profitable investment.
Users should always consult with and obtain advice from their professional licensed financial advisor, including
their tax advisor, to determine the suitability of any investment. INK recommends that anyone making an investment
or trading securities do so with caution. Users should perform full due diligence and investigate any security
fully before making an investment or before the execution of a security trade based upon information learned
through INK. Investors should obtain annual reports and other company information to complete their own due
diligence in any investment. Neither INK nor anyone affiliated with INK is responsible for any investment decision
made. INK employees may have an ownership or investment interest in any stock mentioned in this service or on this
website. On this site, there may be third party content, content from authors or links to third-party sites or
pages, the contents of which are not verified, maintained, controlled or supervised by INK. INK is not responsible
for and assumes no liability for the accuracy, completeness or timeliness of any third party content or authored
content provided herein or the information or contents of any linked sites or pages. The inclusion of any authored
content or link by us does not imply that INK recommends, approves or endorses the authored content or linked site
or pages. INK Edge® and INK Research® are registered trade-marks owned by INK Research Corp. SEDI®
is a registered trade-mark owned by the Alberta Securities Commission.Read less
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.
Interactive technical study charts by TradingView. Copyright © 2024 INK Research Corp. All rights reserved. All trade-marks or trade names not owned by INK Research Corp. are the property of their respective owners.
